The African cholera surveillance network (Africhol) consortium meeting, 10–11 June 2015, Lomé, Togo by Aline Munier et al.
BMC ProceedingsThe Author(s) BMC Proceedings 2017, 11(Suppl 1):2DOI 10.1186/s12919-016-0068-zMEETING REPORT Open AccessThe African cholera surveillance network
(Africhol) consortium meeting, 10–11 June
2015, Lomé, Togo
Aline Munier1*, Berthe-Marie Njanpop-Lafourcade1, Delphine Sauvageot1, Raymond B. Mhlanga2,
Léonard Heyerdahl2, Johara Nadri1, Richard Wood3, Issaka Ouedraogo4, Alexandre Blake1,17,
Laurent Akilimali Mukelenge5†, Jean-Claude B. Anné6†, Abiba Banla Kere7†, Lucienne Dempouo8†,
Sakoba Keita9†, José P. M. Langa10†, Issa Makumbi11†, Elibariki R. Mwakapeje12†, Ian J. Njeru13†,
Olubunmi E. Ojo14†, Isaac Phiri15†, Lorenzo Pezzoli16, Bradford D. Gessner1 and Martin Mengel1From Africhol Consortium Meeting 2015
Lome, Togo. 10-11 June 2015Abstract
The fifth annual meeting of the African cholera surveillance network (Africhol) took place on 10–11 June 2015 in Lomé,
Togo. Together with international partners, representatives from the 11 member countries -Cameroon, Côte d’Ivoire,
Democratic Republic of Congo, Guinea, Kenya, Mozambique, Nigeria, Tanzania, Togo, Uganda, Zimbabwe- and an
invited country (Malawi) shared their experience. The meeting featured three sessions: i) cholera surveillance,
prevention and control in participating countries, ii) cholera surveillance methodology, such as cholera mapping, cost-
effectiveness studies and the issue of overlapping epidemics from different diseases, iii) cholera laboratory diagnostics
tools and capacity building. The meeting has greatly benefitted from the input of technical expertise from participating
institutions and the observations emerging from the meeting should enable national teams to make
recommendations to their respective governments on the most appropriate and effective measures to be taken for the
prevention and control of cholera.
Recommendations for future activities included collecting precise burden estimates in surveillance sites; modeling
cholera burden for Africa; setting up cross-border collaborations; strengthening laboratory capacity for the confirmation
of suspected cholera cases and for vaccine impact assessment in settings where oral cholera vaccine would be used;
adapting cholera surveillance to concurrent issues (e.g., Ebola); and developing national cholera control plans including
rationale vaccination strategies together with other preventive and control measures such as improvements in water,
sanitation and hygiene (WASH).
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Cholera remains a substantial contributor to public
health burden in many developing countries, particularly
in sub-Sahara Africa. In 2014, 190,549 cases were re-
ported to the World Health Organization (WHO), in-
cluding 55% from Africa [1]. Of the 2,231 deaths
reported worldwide, 1882 (84.4%) occurred in Africa.
However, the true burden of cholera is poorly known
and likely underestimated, because of limitations in
current national surveillance systems including under-
reporting, type of case-definitions used and lack of la-
boratory diagnostic capacities. An estimated 2.9 million
cholera cases (1.3 m–4.0 m) and 95,000 cholera deaths
(21,000-143,000) occur each year [2].
Targeting cholera prevention through increased access
to water, sanitation and hygiene (WASH) and oral chol-
era vaccines (OCV) requires accurate epidemiological
data at the local level. Further, such data help inter-
national organizations to prioritize where to support the
places most in need.
The African Cholera Surveillance Network [3] was
launched in 2009 as a consortium of organizations with
expertise in cholera prevention and control and is man-
aged and technically supported by the Agence de Méde-
cine Préventive (AMP). It aims to generate data to
enable national and international stakeholders determine
the most appropriate interventions for prevention and
control of cholera. Africhol supports countries by imple-
menting a common protocol for data collection and ana-
lysis and building capacity for cholera diagnosis.
Study methods have been approved for each country
by national ethical review boards or public-health au-
thorities. The project has created a sustainable network
for prospective cholera surveillance in high-incidence
areas of 11 African countries: Cameroon, Côte d’Ivoire,
Democratic Republic of the Congo (DRC), Guinea,
Kenya, Mozambique, Nigeria, Tanzania, Togo, Uganda,
and Zimbabwe. The National Institute for Communic-
able Diseases (NICD) in South Africa participates for
laboratory quality control and genotyping. Africhol is
part of the Global Task Force on Cholera Control
(GTFCC) at WHO, which aims to support increased
implementation of evidence-based strategies to control
cholera [4].
The annual Africhol consortium meeting enables
countries and partners to exchange on recent updates.
The objectives of the fifth annual meeting, held in Lomé,
Togo, in 10–11 June 2015, were to:
 Share the results of Africhol surveillance for 2011–
2015;
 Identify trends in cholera epidemiology in Africa;
 Share experiences in the fight against cholera and
promote dialogue and discussion; Strengthen country capacity including spatial data
analysis and laboratory diagnostics.
 Apply results and experiences to cholera prevention
interventions, including vaccine use.
Fifty-two participants attended, including 28 affiliated to
Ministries of Health, 16 from international institutions
and 8 from academic institutions (Additional file 1).
Cholera surveillance, prevention and control in Africhol
countries
According to the WHO standard case definition, a case
of cholera should be suspected when:
– in an area where the disease is not known to be
present, a patient aged 5 years or more develops
severe dehydration or dies from acute watery
diarrhea;
– in an area where there is a cholera epidemic, a
patient aged 5 years or more develops acute watery
diarrhea, with or without vomiting.
In each Africhol country, this definition was adapted
and varied based on the project’s goals and the country
preferences, including using a younger age threshold
and less restrictive clinical criteria.
A case of cholera was considered confirmed when
Vibrio cholerae O1 or O139 was isolated from a patient
with diarrhea.
Cholera epidemiology in Africhol countries 2011–2015
General patterns and local specificities of cholera epi-
demiology in Africhol countries emerged through the
presentations and discussions, including:
 Age distribution: the majority of suspected cases
were 15 to 59 years-old but a substantial proportion
of suspected and confirmed cases were seen in
children below age 5 years, especially in Goma,
DRC. This highlights the lack of sensitivity of the
WHO cholera case-definition used by most African
countries that excludes persons under 5 years old.
Zimbabwe, for example reacted after the 2008
cholera outbreak by changing the case definition to
include cases 2 years and above.
 Symptomatology: over 80% of all cases had acute
watery diarrhea, vomiting and severe dehydration.
The distribution of clinical signs differed between
countries. When applying the WHO case definition
to the cases in our network, we found it to have
high sensitivity but low specificity. For Africhol, we
increased specificity by confirming all clinically
suspected cases by laboratory culture whenever
possible. Using Africhol data we are working to
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combinations of clinical signs showing that
including cases age 2 years and above significantly
increases sensitivity without decreasing specificity
compared to the WHO case definition.
 Endemic vs. epidemic cholera: different
epidemiological patterns for cholera disease were
identified [5]. In certain countries such as the DRC,
cases are reported throughout the year, especially in
well delimited areas of hyper endemicity (i.e.,
“cholera hotspots”). Outbreaks may occur at
irregular intervals in other countries, such as in Côte
d’Ivoire, with an epidemic in 2014, or in Guinea
where a very large outbreak occurred in 2012 with
sporadic cases confirmed before and after this
epidemic. In 2015, major epidemics occurred in East
Africa associated with seasonal floods, in particular
in Mozambique, Malawi, Zimbabwe, Kenya, and
Tanzania.
 Identified groups at risk of cholera: according to the
countries, geographic case clusters were observed,
such as in specific neighborhoods of Lomé. Specific
populations at risk also represented a large
proportion of cholera cases identified:
– Internally displaced persons (IDPs), refugees and
slum dwellers: in Goma, DRC, higher cholera
burden was seen during the military conflict, and
successive waves of the epidemic followed
population movements. After the dismantling of
IDP camps in 2014, cases declined. In Cameroon
in 2014, many cases concentrated on the border
with Nigeria where conflicts were ongoing. In
Kenya, large national outbreaks started in Nairobi
slums. In Tanzania an outbreak occurred in
Kigoma region in May 2015 in the camps for
refugees and asylum seekers, claiming 4,487 cases
and 31 deaths.
– Fishing communities: for example, in Abidjan,
Côte d’Ivoire, that may play a role in the start of
epidemics and act as vectors in transmitting the
disease to resident populations. In Uganda,
outbreaks also occur regularly in fishing
communities, such as in Namayingo district in
2014. Africhol has implemented anthropological
studies to better understand specific population
practices and acceptance of interventions, and to
adapt prevention and education messages.
– These high-risk groups usually shared the same
characteristics regarding WASH, with a low pro-
portion of households with latrine coverage and
access to safe drinking water. Improved detection,
diagnosis, and reporting, as already done in
Africhol countries, will be critical to improve
context-adapted WASH interventions [6]. Cross-border transmission: cholera endemic areas or
populations are often independent from national
borders. Hence, cross-border transmission is a con-
cern, because of population movements and charac-
teristics of specific populations such as fishermen
who frequently cross riverine, lacustrine, or marine
borders for occupational reasons. Africhol has been
instrumental in starting discussion between several
of its member countries to set up cross-border sur-
veillance. For example, Uganda with Kenya and DR
Congo, or Guinea-Conakry and its neighbors (Sierra
Leone) has occurred and, during an outbreak in
Zimbabwe in 2015, discussions started with
Mozambique and Malawi. Some of the cross-border
affected countries have started to initiate a dialogue,
either during regional meetings, specific cross-
border meetings at national level or directly in the
districts concerned, in particular discussing the pos-
sibility to exchange data from cholera line lists, and
to implement common control measures during an
outbreak. For countries developing or adapting their
national plan for the control and prevention of chol-
era, cross-border collaboration was added as a spe-
cific component of the plan, highlighting the
importance of this concern.
Response to epidemics and experience with OCV
 From an international perspective
The long-term solution for cholera control remains
increasing access to safe drinking water, hygiene and
improved sanitation infrastructures, provided the
latter is adapted to the local context. However,
employing OCV has proven effective in reactive
campaign in Africa [7]. Further, OCV has recently
been shown to have a protective efficacy for at least
5 years [8]. This opens the possibility for preventive
use of OCV in locations that are historically at high
risk of cholera, especially in sites with low access to
care and where it is not feasible to improve health
and sanitation conditions in the short term. OCV
can serve as a short- and medium-term step in con-
trolling cholera while longer term solutions are put
in place or where such solutions are difficult to put
in place, e.g., in migrant populations. In October
2009, the WHO Strategic Advisory Group of Experts
on immunization (SAGE) recommended that OCV
should be considered as a reactive strategy during
outbreaks, in addition to the already recommended
preventive use in endemic areas [9]. A new bi-valent
killed whole cell vaccine was pre-qualified by WHO
in 2011 and a stockpile was created in 2013, with an
initial two million doses to be available mainly for
epidemic response in low-income countries, which
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Vaccine Alliance. In this context, more governments
might consider cholera vaccination where needed
[10]. Countries wishing to use the vaccine can re-
quest doses through two different mechanisms: 1)
for emergency situations (i.e., responding to cholera
outbreaks or humanitarian crises), the vaccine stock-
pile is managed by the International Coordinating
Group (ICG) and 2) for non-emergency situations
(i.e., conducting preventive vaccination campaigns in
cholera hotspots) OCV is managed by the OCV
Working Group of the GTFCC.
 From a national perspective
In 2015, two countries had different experiences
requesting OCV doses in response to a cholera epidemic:
– In Malawi, floods affected 15 districts in the country
in January 2015, causing the displacement of
230,000 people living in temporary camps. In
February, a cholera outbreak started in the
community in the Nsanje district, one of the most
affected by the floods; this outbreak accounted for
58 of 78 suspected cholera cases nationally during
this period, and was associated with two deaths. To
prevent the spread of cholera to the IDP camps and
the surrounding community, in March 2015 a
request was submitted to the ICG and approved.
The campaign in Nsanje targeted 160,000 people
living in the IPD camps and the surrounding
community. The campaign’s strengths included: very
high administrative coverage in the first round
(98%); availability of resources (vaccines, transport
and cold chain); and strong motivation of health
personnel and community leaders. Challenges
included difficulties in administering the second
dose, with 70% coverage (bad taste and smell,
movement of the initially vaccinated populations);
increased workload for health workers; and
misinformation (people presenting for the first
injection at the second round).
– Mozambique also faced a large epidemic in January-
April 2015, when heavy rainfall was associated with
more than 7,000 suspected cases and 59 deaths in
five provinces together, including 1453 cases and 14
deaths in Zambezia province alone. The country de-
cided to undertake an OCV campaign, whose goal
was to prevent epidemic spread to the town of Que-
limane (an important trade route) and the IDP
camps in Zambezia province, which had limited ac-
cess to clean water and latrines. A request for
181,496 OCV doses was submitted to the ICG in
April 2015. The ICG declined the request arguing
that a reactive campaign would have had a limitedimpact because the cholera epidemic was already de-
creasing in all affected areas including in the districts
targeted for vaccination. This experience shows how
important it is to continuously collect and use sur-
veillance data and to have a clear strategy in place
for OCV use, ideally incorporated into a national
cholera control plan, and to anticipate administrative
and logistical constraints, as well as the role of the
national regulatory agency, to plan timely vaccin-
ation strategies.
Cholera surveillance methodology
Overlapping epidemics from different diseases: Ebola and
cholera
Ebola has affected cholera-prone countries, including
Guinea which is part of the Africhol consortium. Follow-
ing the challenges for the health system, e.g., the loss of
staff to disease and death, the threat of overlapping sim-
ultaneous epidemics is imminent. Therefore we have
adapted cholera surveillance as follows:
– Extension of Africhol enhanced surveillance to
coastal areas at high risk for the onset of cholera
epidemics (which are also sites affected by Ebola in
2014–2015).
– Digital reporting in one pilot prefecture for instant
data accessibility from prefecture to central level.
– No stool samples collected or tested to avoid risk of
contamination by Ebola virus, as instructed by the
Ministry of Health. This lack of case confirmation
could have led to false cholera notifications due to
diarrhea from other etiologies. To prevent this, we
used an adapted and simplified case-report form
mainly focusing on signs more specific to Ebola to
distinguish cholera from Ebola. These signs included
the presence of unexplained bleeding, unconscious-
ness, fever, and contact with an Ebola case.
Issues around both diseases can be dealt with through
an integrated approach:
– Given the difficulties in monitoring and confirming
both diseases and their overlapping case-definitions,
a different case definition for cholera could be con-
sidered that might, for example, include the absence
of fever as a way of distinguishing it from Ebola.
– The Ebola epidemic may have resulted in increased
hygiene education campaigns and training of
community members to detect signs of Ebola (and
potentially cholera), which in turn may have made
communities more resilient.
– Both diseases need strengthened surveillance
including improved laboratory capacity in optimal
safety conditions. This includes developing enhanced
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diagnostic tests (RDTs) on stools that have been
rendered safe through chlorination, radiation, or
other measures; and considering the duration of
Ebola virus shedding in stool.
– The use of OCV could be considered preemptively
in populations at high risk of cholera and Ebola [11],
potentially together with an Ebola vaccine that may
be available in the future.
Cholera risk mapping in Africa
Work on the dynamics of cholera in Africa by Johns
Hopkins Bloomberg School of Public Health (Lessler,
Azman et al.) used a large variety of official and unoffi-
cial reporting sources to detect regions with strong regu-
lar transmission compared to irregular transmission and
to evaluate areas or hotspots where health interventions
would have the most impact. In DRC, for example, chol-
era circulates endemically at a moderate incidence level
but with very high regional differences, with 9% of the
population living in areas where the incidence is higher
than 1/1000.
For further analyses, it will be important to include de-
tailed information on fatality ratios, as many countries
that do not systematically report deaths may have the
highest case fatality ratios.
Cost-effectiveness of immunization strategies
In a context of limited resources, the use of cost-
effectiveness models is of particular interest in helping
decision-makers choose optimal intervention strategies.
The cost-effectiveness of various OCV immunization
strategies was presented by the representative of Fred
Hutchinson Cancer Research Center, Seattle, USA. Using
the examples of Goma (DRC), Bangladesh and Haiti, it
showed that targeting different specific population
groups (in terms of age, incidence of the disease) will
affect the impact and, therefore, be more or less cost ef-
fective. In addition, the costs and benefits of interven-
tions may differ depending on the implementing entity
(government, private sector, communities). More com-
plex models may take into account herd immunity and
compare different strategies (e.g., single dose vaccination
vs. campaigns every few years).
Cholera laboratory diagnostic tools and capacity
building
Cholera diagnosis in Africa
Within the Africhol project, suspected cases of cholera
should be confirmed by laboratory diagnosis whenever
possible. More than half of the suspected cases had a
stool sample collected, with 37% having a positive cul-
ture. Great disparities existed between countries, with
positivity rates ranging from less than 30% (Kenya andMozambique) to over 60% (Togo, Tanzania and
Zimbabwe). The predominant serotypes also varied be-
tween countries, with mainly Ogawa (Guinea and Togo)
in some and Inaba (DRC and Tanzania) in others. Exter-
nal quality control was set up at the National Institute
for Communicable Diseases (NICD) in Johannesburg,
South Africa. An increase in antibiotic resistance oc-
curred during the study period, potentially due to high
self-medication and the use of antibiotics for treating
other diseases.
A variety of new technologies are becoming available
for rapid and multiplex testing of Vibrio cholerae. How-
ever, they must become more accessible and affordable
for use in low-resource settings.
Laboratory capacity strengthening and technology
transfer
Within the Africhol project, laboratory capacity for the
confirmation of Vibrio cholerae was developed to obtain
more precise burden estimates. We reinforced the oper-
ational capacity of the provincial laboratory in Goma,
DRC (Ami Labo), thereby illustrating how high-quality
bacteriological diagnostics can be adapted to challenging
low-resource settings. This reinforcement resulted in a
substantial increase in the number of strains analyzed in
Goma, from 450 between 1998 and 2010 to 1,350 be-
tween 2011 and May 2015. Further knowledge transfer
was provided in all Africhol countries. In addition, staff
of AMP and the University of Gothenburg trained biolo-
gists at the consortium meeting on molecular techniques
to isolate and identify V. cholerae in stool.
Collection of environmental data
Environmental surveys were carried out in 2014 in en-
hanced surveillance sites in Lomé and Goma. Water and
fish samples were taken monthly for six months. In
addition, samples were taken at the home of cases dur-
ing outbreak investigations. In Togo, no V. cholerae were
identified in the environment in the absence of an epi-
demic, while during epidemics V. cholerae O1 Ogawa
was identified in 4 of 6 case contacts (persons living in
the same compound as the case, including case house-
holds and other households sharing the same well) and
in their environment (two wells and bath water in one
instance), and three Vibrio spp were found in (one each
in a well, public restroom and drinking water). In Goma,
DRC, the local laboratory found V. cholerae O1 Hiko-
jima (3), non O1 non O139 (19), and O139 strains (3) in
lake water and in caught Tilapia fish.
Research on V. cholerae pathogen and cholera vaccines
Colleagues Lebens and Karlsson from the University of
Gothenburg, Sweden, shared their experience and know-
ledge, co-organized the laboratory workshop and met
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international level. They presented their ongoing work
on differences in the observed persistence of V. cholerae
strains in India, possibly correlated to mutations in the
gene that determines the Ogawa/Inaba serotype and its
implications for allowing early detection of epidemic-
prone strains. They also updated the group on a current
research towards simplified, cheap and low-cost cholera
vaccines that could be potentially field-tested in cholera-
affected countries in the future.
Recommendations and conclusions
Conclusions from the meeting
The implementation of this multi-country project in Africa
within a consortium of institutions and countries has en-
abled common working standards; progress in networking,
including South-South and North–South collaboration and
international mobilization; improved political support and
willingness to address cholera control; knowledge transfer
and capacity building; and financial support and sustain-
ability through distribution of work between partners.
Over 10,000 suspected cases have been reported and
over 5,000 stool samples tested during the 5 years of sur-
veillance. Initially, only aggregated notifications of chol-
era by year and country were available. Now the number
of suspected and confirmed cases at neighborhood level,
including morbidity and mortality, is known for specific
areas, such as villages and urban neighborhoods. We be-
lieve that understanding cholera epidemiology at this
level is necessary as prevention and control interven-
tions are implemented locally and therefore national
level data are of limited use in planning impactful
interventions.
Another important but underappreciated dimension of
cholera epidemiology – and one missing from aggre-
gated surveillance data – is population behaviours that
increase cholera risk. These behaviours may impact all
interventions, including WASH and vaccine use. Finally,
OCV availability represents a new opportunity for chol-
era control, and countries may apply for the vaccine at
the ICG (for use in emergency settings) or at the
GTFCC (for preemptive use).
Recommendations for future public-health work and re-
search activities on cholera and OCV
Cholera surveillance
– Improve epidemiological surveillance and laboratory
capacity for cholera diagnosis (especially at regional
and district levels) to better document disease
burden, plan timely prevention and response
measures including context-adapted WASH activ-
ities and assess the impact of future OCV
immunization campaigns.– Adapt the case definition in high-burden areas to in-
clude children age 2 years and above since many
cases in Africhol countries were in the 2–5 year-old
age group.
– Adapt cholera surveillance to the broader context of
overlapping epidemics of different diseases, for
example Ebola.
– Test new tools and technologies such as real-time
case reporting.
– Continue to identify hotspots, with refinement of
hotspot definitions to include the characterization of
high-risk groups in addition to geographical criteria.
– Directly brief provincial and municipal authorities
on the existing high-burden areas under their
authority.
– Routinely assess behavioural indicators such as
(seasonal) migration patterns and age and gender
specific risk behaviours, at least in high-burden
areas.
Cholera diagnostic tools
– Improve the sensitivity and specificity of existing or
new RDTs, and lower their cost to make them more
useful for individual diagnosis and epidemiologic
studies.
Research on OCV use
– Conduct more studies to evaluate preventive use
of OCV in endemic settings, in addition to the
focus on reactive campaigns in emergency
settings.
– Test simplified immunization strategies. The
current guidelines recommend the administration
of two doses of the Shanchol™ vaccine; a single
dose strategy could be explored to determine
whether it provides rapid immunity in
populations that were naturally immunized or
previously vaccinated [12–15].
– Evaluate OCV field effectiveness outside the cold-
chain or in specific settings (schools, etc.); assess
OCV safety and effectiveness in specific groups
(pregnant women, travelers); and further
characterize herd protection.
– Model interventions to prevent outbreaks to
determine optimal strategies for different
epidemiological contexts [12, 16, 17].
– Conduct cost-effectiveness analyses for low resource
settings [18, 19].
– Investigate knowledge, attitudes and practices of
specific high-risk groups (such as fishing communi-
ties) through anthropological studies, to adapt pre-
vention and control strategies.
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continuing and expanding North–South collaborations
on specific projects with universities and non-
governmental organizations working in the field of pub-
lic health, research and infectious diseases, and with
support from international organizations and partners,
such as Gavi, BMGF, WHO (GTFCC) and bilateral aid
agencies. Each country should determine its own prior-
ities according to its political and epidemiological con-
text. Countries should develop a multi-year plan for the
prevention and control of cholera, which will also pro-
vide a road map for partners wishing to support cholera
control activities.
Recommendations for evidence-based health policy re-
garding cholera
– Develop guidelines on the rationale use of OCV
and integrated national cholera plans for easier
decision-making in preparing for immunization
campaigns, in addition to context-adapted long-term
WASH interventions.
– Strengthen surveillance systems including laboratory
diagnostic capacity to allow early detection of
epidemics and appropriate response and control.
– Train health personnel in the diagnosis,
management and reporting of cases.
– Better document country cholera features and
continue research on cholera and OCV.
– Have functional National Immunization Technical
Advisory Groups (NITAGs) to support decisions-
makers in taking evidence-based decisions on con-
trol measures including the use of vaccine.
– Strengthen cross-border collaboration between at-
risk countries, to enhance joint surveillance, diagnos-
tics and reporting of cholera and other priority
cross-border health issues for mutual benefits.
– Prepare to strengthen, expand and sustain the Africhol
consortium. The gains that have been made must be
backed up by strong North-South cooperation via
complementary projects, as well as South-South
cooperation as has already been initiated.
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